Upper Limb Tremor Reduction in Essential Tremor Patients

Completed · Not applicable

Conditions studied: Essential Tremor

In brief

This study is designed to demonstrate the safety, tolerability, and efficacy of the Encora Therapeutics Tremor Mitigation Device in subjects with upper limb tremor caused by Essential Tremor.

Key facts

Study ID

NCT06343285

Run by

Encora, Inc.

People needed

71

Starts

2024-01-01

Expected to finish

2024-11-12

Last updated by the study team

2025-10-01

Who can join

Age: 22 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Between the ages of 22 and 80 years of age
• A diagnosis of essential tremor (definite or probable based on TRIG criteria)
• At least one hand exhibiting tremor > 2 as assessed by the Essential Tremor Rating
• Assessment Scale (TETRAS) finger to nose task, duck wing task, OR Archimedes Spiral completed during the Screening visit
• Stable tremor medications for at least 30 days prior to enrollment and the ability to maintain stable medications through the duration of the study
• Randomization Inclusion Criteria
• During the Baseline evaluation period, a median tremor score of > 2 on at least one hand as assessed by the TETRAS finger to nose task, the duck wing task, OR the Archimedes Spiral AND
• During the Baseline evaluation period, a median score of > 3 on any one of the subject-assessed items of the Bain \& Findley Activities of Daily Living Scale (BF-ADL)

You may not qualify if…

• Previous surgical interventions for tremor reduction on the upper limb being used for inclusion in this study (eg, thalamotomy procedure, including Stereotactic Thalamotomy, Gamma Knife Radiosurgical Thalamotomy, or focused ultrasound)
• Use of botulinum toxin for treatment to hand tremor within six months of enrollment
• Suspected or diagnosed epilepsy or other seizure disorder
• Other possible causes of tremor, including Parkinson's disease, drug-induced tremor, or dystonia
• Pregnant
• Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at stimulation site
• Numbness, tingling or pain affecting the tested upper extremity (eg, suspected or confirmed peripheral neuropathy, carpal tunnel syndrome)
• Known allergy to silicone
• Subjects are unable or unwilling to comply with the protocol requirements
• Subject is part of a vulnerable population who is unable to give Informed Consent for reasons of incapacity, dementia, immaturity, adverse personal circumstances or lack of autonomy. This may include individuals with mental disability, persons in nursing homes, children, impoverished persons, persons in emergency situations, homeless persons, nomads, refugees, and those incapable of giving informed consent.
• Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention.

Where it is running

• Encora Therapeutics — Cambridge, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.